Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a consensus rating of “Moderate Buy” by the twenty-seven brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $478.6688.

A number of research firms recently weighed in on ALNY. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Bank of America increased their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Truist Financial lifted their target price on Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, Royal Bank Of Canada increased their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael W. Bonney sold 11,250 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director owned 16,804 shares in the company, valued at approximately $7,561,800. The trade was a 40.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 98,144 shares of company stock valued at $44,160,261 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Teacher Retirement System of Texas lifted its holdings in shares of Alnylam Pharmaceuticals by 3.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after acquiring an additional 1,123 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 33.0% during the second quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock valued at $31,238,000 after buying an additional 23,749 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth approximately $275,000. Finally, Strs Ohio bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $7,781,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.5%

Alnylam Pharmaceuticals stock opened at $442.70 on Friday. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The firm has a market capitalization of $58.49 billion, a price-to-earnings ratio of -179.23 and a beta of 0.30. The firm has a 50 day moving average of $458.74 and a 200 day moving average of $376.00. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $1.39 by $1.51. The business had revenue of $1.25 billion for the quarter, compared to the consensus estimate of $943.37 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s revenue for the quarter was up 149.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.